Abstract
Inflammatory bowel diseases (IBDs) are chronic and involve the gastrointestinal tract; the two primary IBDs are ulcerative colitis and Crohn’s disease. Existing treatments for IBD include control of active inflammation and regulation of immune disorders, and commonly used drugs include salicylates, corticosteroids, and immunosuppressants. At the same time, an in-depth study of IBD pathogenesis promoted the acceptance of bioimmunotherapy by increasing numbers of people. However, long-term use of these drugs can cause adverse reactions that are difficult for patients to overcome, with limited efficacy for critically ill patients. Recent studies have found that stem cell transplantation is a new and effective therapy and IBD treatment, particularly for refractory cases. Stem cells, especially induced pluripotent stem cells (iPSCs), can differentiate into functional intestinal epithelia and their use avoids ethical issues arising from embryonic stem cells, providing a new kind of seed cell for alternative treatments for IBD. This paper reviews iPSCs as a potential new treatment for IBDs in order to provide an experimental and clinical reference.
Keywords: Induced pluripotent stem cells, inflammatory bowel diseases, intestinal epithelial cell, reprogramming.
Current Stem Cell Research & Therapy
Title:Applications of Induced Pluripotent Stem Cells in the Modeling of Human Inflammatory Bowel Diseases
Volume: 10 Issue: 3
Author(s): Jingquan Liu, Bin Shi, Kai Shi and Hongze Zhang
Affiliation:
Keywords: Induced pluripotent stem cells, inflammatory bowel diseases, intestinal epithelial cell, reprogramming.
Abstract: Inflammatory bowel diseases (IBDs) are chronic and involve the gastrointestinal tract; the two primary IBDs are ulcerative colitis and Crohn’s disease. Existing treatments for IBD include control of active inflammation and regulation of immune disorders, and commonly used drugs include salicylates, corticosteroids, and immunosuppressants. At the same time, an in-depth study of IBD pathogenesis promoted the acceptance of bioimmunotherapy by increasing numbers of people. However, long-term use of these drugs can cause adverse reactions that are difficult for patients to overcome, with limited efficacy for critically ill patients. Recent studies have found that stem cell transplantation is a new and effective therapy and IBD treatment, particularly for refractory cases. Stem cells, especially induced pluripotent stem cells (iPSCs), can differentiate into functional intestinal epithelia and their use avoids ethical issues arising from embryonic stem cells, providing a new kind of seed cell for alternative treatments for IBD. This paper reviews iPSCs as a potential new treatment for IBDs in order to provide an experimental and clinical reference.
Export Options
About this article
Cite this article as:
Liu Jingquan, Shi Bin, Shi Kai and Zhang Hongze, Applications of Induced Pluripotent Stem Cells in the Modeling of Human Inflammatory Bowel Diseases, Current Stem Cell Research & Therapy 2015; 10 (3) . https://dx.doi.org/10.2174/1574888X09666140820162716
DOI https://dx.doi.org/10.2174/1574888X09666140820162716 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Current Medicinal Chemistry Recent Patents on Genes and Gene Sequences Useful for Developing Breast Cancer Detection Systems
Recent Patents on DNA & Gene Sequences DNA Mismatch Repair Deficiency, Resistance to Cancer Chemotherapy and the Development of Hypersensitive Agents
Current Topics in Medicinal Chemistry The Emerging Role of Unmetabolized Folic Acid in Human Diseases: Myth or Reality?
Current Drug Metabolism Pharmacogenetics of Cytochrome P450 (CYP) 1A2 and Variability in Psychotropic Drug Response
Current Psychiatry Reviews Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Pharmacokinetic and Metabolism of PET Radiotracers for Imaging P-glycoprotein in Chemoresistant Tumor of Colorectal Cancer
Current Drug Metabolism Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Diverse Functions of γ -secretase: Releasing Signaling Fragments and Deleterious Molecules
Current Enzyme Inhibition The Potential of Natural Products as Effective Treatments for Allergic Inflammation: Implications for Allergic Rhinitis
Current Topics in Medicinal Chemistry Camptothecin: Therapeutic Potential and Biotechnology
Current Pharmaceutical Biotechnology Editorial (Hot Topic: Artificial Intelligence Techniques in Medicinal Chemistry)
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Advances in Biomarker Research for Pancreatic Cancer
Current Pharmaceutical Design DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Targeting Glioblastoma: The Current State of Different Therapeutic Approaches
Current Neuropharmacology Novel Anti-Angiogenic Compounds for Application in Tumor Therapy – COP9 Signalosome-Associated Kinases as Possible Targets
Mini-Reviews in Medicinal Chemistry Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
Current Cancer Drug Targets